Home › Multiple Myeloma › Michigan › Detroit
Pag-aaral pangklinika para sa Multiple Myeloma sa Detroit, MI
19 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Detroit (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Nagre-recruitPhase 4
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Karmanos Cancer Institute, Detroit
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Nagre-recruitPhase 3
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
- Henry Ford Health Saint John Hospital, Detroit
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Nagre-recruitPhase 3
- Henry Ford Health System, Detroit
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Nagre-recruitPhase 3
- Henry Ford Health Saint John Hospital, Detroit
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Nagre-recruitPhase 1/2
- Karmanos Cancer Institute, Detroit
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Detroit
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Detroit
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Karmanos Cancer Institute, Detroit
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Nagre-recruitPhase 1
- Karmanos Cancer Institute, Detroit
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Nagre-recruitPhase 4
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Nagre-recruitPhase 2
- Karmanos Cancer Institute, Detroit
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Nagre-recruitPhase 3
- Ascension Saint John Hospital, Detroit
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Karmanos Cancer Institute, Detroit
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Nagre-recruitPhase 1/2
- Karmanos Cancer Institute, Detroit
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Nagre-recruitPhase 3
- GSK Investigational Site, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Nagre-recruit
- Karmanos Cancer Institute, Detroit
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO27 pag-aaral
- St. Louis, MO24 pag-aaral
- Rochester, MN24 pag-aaral
- Columbus, OH24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- Edison, NJ22 pag-aaral
Iba pang pag-aaral sa Detroit
- Non-Small Cell Lung Cancer44 pag-aaral
- Kanser sa Suso33 pag-aaral
- Kanser (lahat ng uri)29 pag-aaral
- Colorectal Cancer26 pag-aaral
- Kanser sa Ovary26 pag-aaral
- Metastatic Cancer24 pag-aaral
- Kanser sa Prostate22 pag-aaral
- Kanser ng Endometrium21 pag-aaral
- Kanser sa Baga20 pag-aaral
- Kanser sa Tiyan16 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg15 pag-aaral
- Acute Myeloid Leukemia14 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.